Remote Temperature Data for Early Detection of Febrile Neutropenia

Hematologic Malignancy Clinical Trial

Official title: Remote Data Capture of Elevated Temperature Data for Early Detection of Febrile Neutropenia in Patients With Hematologic Malignancies

Status Active, not recruiting

Clinical Trial Summary

BioSticker data is remotely tracked and displayed in a report termed the BioReport for retrospective data analysis. Typically, the biosensor collects data on an interval of ~1 minute and this data is collated and reported remotely back to the BioReport every 6 hours. More importantly, for future applications of the BioSticker for early detection of FN, there are ongoing efforts to implement real time reporting and alarms using remote monitoring services that could alert the patient that they need to seek medical care. There are no known deleterious effects from the BioSticker and it is now being widely used and tested in diverse applications including detection and contact tracing of COVID and others.

Clinical Trial Description

The BioIntelliSense BioSticker potentially offers a solution to these challenges through early and reliable detection of elevated temperature and perhaps other relevant physiologic changes. The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring (see https://biointellisense.com as well as attached documents on BioSticker instructions for a full description and use instructions). The BioSticker detects the following:

• Respiratory rate, heart rate at rest and skin temperature

• Body position, activity levels, sleep status

• High-resolution gait analysis and fall detection

• Symptomatic events

BioSticker data is remotely tracked and displayed in a report termed the BioReport for retrospective data analysis. Typically, the biosensor collects data on an interval of ~1 minute and this data is collated and reported remotely back to the BioReport every 6 hours. More importantly, for future applications of the BioSticker for early detection of FN, there are ongoing efforts to implement real time reporting and alarms using remote monitoring services that could alert the patient that they need to seek medical care. There are no known deleterious effects from the BioSticker and it is now being widely used and tested in diverse applications including detection and contact tracing of COVID and others. ;

Related Conditions & MeSH terms

• Febrile Neutropenia
• Hematologic Malignancy
• Hematologic Neoplasms
• Neoplasms
• Neutropenia

• NCT number: NCT05180838
• Study type: Observational
• Source: University of Colorado, Denver
• Status: Active, not recruiting
• Start date: October 7, 2021
• Completion date: September 1, 2025